SynthesisPloS one2018
TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: A meta-analysis.
Synthesis in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Diagnostic Accuracy of Blood-based Biomarkers for Pancreatic Cancer: A Systematic Review and Meta-analysis.Cancer research communications · 2022Pooled it
- Evaluation of a research use only (RUO) TIMP-1 assay for use with the automated AlinityBiochemistry and biophysics reports · 2026Article
- Proteomic Portrait of Degranulation Program in Human Circulating Neutrophils Upon Multi-Inflammatory and Infectious Activation.Molecular & cellular proteomics : MCP · 2026Article
- From Lab to Clinic: Artificial Intelligence with Spectroscopic Liquid Biopsies.Diagnostics (Basel, Switzerland) · 2025Review
- Identification and Validation of Biomarkers to Predict Early Diagnosis of Inflammatory Bowel Disease and Its Progression to Colorectal Cancer.Biochemical genetics · 2025Article
- Fundamentals and research progression on electrochemical sensing of colorectal cancer.Mikrochimica acta · 2025Review
- Article
- Bioinformatics and experimental unveiling of TIMP1 as a novel therapeutic target in colorectal cancer ferroptosis.Frontiers in oncology · 2025Article
- Prognostic value of metal-based ferroptosis and cuproptosis genes and score in lower grade gliomas.Frontiers in immunology · 2025Article
- Single-cell RNA sequencing of appendiceal adenocarcinoma reveals a low proportion of epithelial cells and a fibroblast enriched tumor microenvironment.ESMO gastrointestinal oncology · 2024Article
- The TIMP protein family: diverse roles in pathophysiology.American journal of physiology. Cell physiology · 2024Review
- Editorial: Recent developments in clinical biomarkers for cancer prognosis, prediction, treatment, and their clinical utility.Frontiers in genetics · 2024Article
- Blood-based biomarkers and novel technologies for the diagnosis of colorectal cancer and adenomas: a narrative review.Biomarkers in medicine · 2024Review
- Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer.Pharmaceutics · 2023Article
- Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics.Nature biotechnology · 2023Article
- Genetic Variants Associated with Acne Vulgaris.International journal of general medicine · 2023Review
- The Probiotic Effects of theJournal of microbiology and biotechnology · 2022Article
- Sp1 induced gene TIMP1 is related to immune cell infiltration in glioblastoma.Scientific reports · 2022Article
- Investigation of proteomic profiles in canine lymphoma using tandem mass tag-based quantitative proteomics approach.Veterinary world · 2022Article
- In silico identification of single nucleotide variations at CpG sites regulating CpG island existence and size.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTissue inhibitor of metalloproteinase-1 (TIMP-1) is a glycoprotein involved in cell survival and tumorigenesis. There have been some promising results regarding the diagnostic value of TIMP-1 for patients with colorectal cancer (CRC). The aim of the present study was to assess the diagnostic accuracy and clinical utility of serum TIMP-1 in CRC patients through meta-analysis.
methodsA systematic search of online databases was performed to collect eligible studies. The pooled sensitivity, specificity, diagnostic odds ratio (DOR), and summary receiver operator characteristic (SROC) curve were generated from accuracy data using the random-effects model. Fagan's nomogram and the likelihood matrix were applied to estimate the clinical utility of TIMP-1.
resultsA total of 9 eligible studies with 1886 patients were included. Among the patients, 819 were pathologically diagnosed with CRC, whereas 1067 did not have adenomas or other cancers. The overall sensitivity, specificity, and DOR of TIMP-1 for the diagnosis of CRC were 0.65 (95% confidence interval (CI): 0.57-0.72), 0.87 (95% CI: 0.76-0.94), and 12.73 (95% CI 5.71-28.38), respectively. The area under the SROC was 0.77 (95% CI, 0.73-0.81), suggesting the potential diagnostic value of TIMP-1 in CRC patients. Among patients with a pretest CRC probability of 20%, posttest probabilities were 56% and 9% for positive and negative TIMP-1 results, respectively.
conclusionsTIMP-1 expression exhibits an upper moderate diagnostic value in CRC, and TIMP-1 assessment may be useful as a noninvasive screening tool for CRC in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.